OXBOF (Oxford BioDynamics) ROC (Joel Greenblatt) %: -194.09% (As of Mar. 2026)


What is Oxford BioDynamics ROC (Joel Greenblatt) %?

Oxford BioDynamics OXBOF ROC (Joel Greenblatt) % is -194.09% as of Mar. 2026. The stock has 4 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Oxford BioDynamics ranks worse than 78.4% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Oxford BioDynamics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -194.09%.

The historical rank and industry rank for Oxford BioDynamics's ROC (Joel Greenblatt) % or its related term are showing as below:

OXBOF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -565.75   Med: -245.06   Max: -101.17
Current: -197.56

During the past 13 years, Oxford BioDynamics's highest ROC (Joel Greenblatt) % was -101.17%. The lowest was -565.75%. And the median was -245.06%.

OXBOF's ROC (Joel Greenblatt) % is ranked worse than
78.4% of 213 companies
in the Medical Diagnostics & Research industry
Industry Median: -3.02 vs OXBOF: -197.56

Oxford BioDynamics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 7.20% per year.


Oxford BioDynamics  (OTCPK:OXBOF) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Oxford BioDynamics ROC (Joel Greenblatt) % Related Terms


Oxford BioDynamics ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Oxford BioDynamics's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oxford BioDynamics ROC (Joel Greenblatt) % Chart

Oxford BioDynamics Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -172.61 -91.07 -167.35 -191.40 -216.02

Oxford BioDynamics Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -144.18 -235.50 -193.51 -210.69 -194.09

OXBOF vs TMO, DHR, IDXX: ROC (Joel Greenblatt) % Comparison

For the Diagnostics & Research subindustry, Oxford BioDynamics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oxford BioDynamics ROC (Joel Greenblatt) % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Oxford BioDynamics's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Oxford BioDynamics's ROC (Joel Greenblatt) % falls into.



Oxford BioDynamics ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.068 + 0.264 + 0.363) - (1.395 + 0 + 0.386)
=-1.086

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.905 + 0.304 + 0.517) - (1.327 + 0 + 4.4408920985006E-16)
=0.399

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Oxford BioDynamics for the quarter that ended in Mar. 2026 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-11.984/( ( (6.35 + max(-1.086, 0)) + (5.6 + max(0.399, 0)) )/ 2 )
=-11.984/( ( 6.35 + 5.999 )/ 2 )
=-11.984/6.1745
=-194.09 %

Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -194.09% mean?
Oxford BioDynamics (OXBOF) has a ROC (Joel Greenblatt) % of -194.09% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Oxford BioDynamics and its competitors. According to the industry distribution chart, Oxford BioDynamics ranks #167 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 78.4%.
Is Oxford BioDynamics' ROC (Joel Greenblatt) % too high?
Oxford BioDynamics' current ROC (Joel Greenblatt) % is -194.09%. Based on the distribution chart, Oxford BioDynamics ranks #167 out of 213 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Oxford BioDynamics' ROC (Joel Greenblatt) % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Oxford BioDynamics ranks #167 out of 213 companies for ROC (Joel Greenblatt) %. This places Oxford BioDynamics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Diagnostics & Research company?
A good ROC (Joel Greenblatt) % depends on the Medical Diagnostics & Research industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Oxford BioDynamics and its competitors. Oxford BioDynamics's current ROC (Joel Greenblatt) % is -194.09%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford BioDynamics stock overvalued right now?
Oxford BioDynamics (OXBOF) has a current ROC (Joel Greenblatt) % of -194.09%. The current ROC (Joel Greenblatt) % is -194.09%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Oxford BioDynamics (OXBOF), the current ROC (Joel Greenblatt) % is -194.09% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oxford BioDynamics Business Description

Other Exchanges OBD:UKLMQ:Germany
Address John Smith Drive, 3140 Rowan Place, Oxford Business Park South, Oxford, GBR, OX4 2WB
Oxford BioDynamics PLC is a biotechnology company focused on advancing personalized healthcare through the development and commercialization of precision medicine tests for serious and impactful diseases. The company is engaged in the commercialisation of proprietary molecular diagnostics products and biomarker research and development. It has two commercially available products: the EpiSwitch PSE (EpiSwitch Prostate Cancer Detection Test) and EpiSwitch CiRT (Checkpoint Inhibitor Response Test) blood tests. The company generates revenue from the sales of proprietary products and biomarker research and development. Geographically, it generates the maximum revenue from the USA.